Florent Potvain

The discovery of equipotent PPARalpha/gamma dual activators.

D. Grillot, Paul Martres, A. Laroze, 2008, Bioorganic & medicinal chemistry letters.

Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.

D. Grillot, Paul Martres, A. Laroze, 2008, Bioorganic & medicinal chemistry letters.

Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.

Michelle C. Schaeffer, Carol A. Capriotti, Paul E. Lamoureux, 2019, Journal of medicinal chemistry.

Design and evaluation of a novel series of 2,3-oxidosqualene cyclase inhibitors with low systemic exposure, relationship between pharmacokinetic properties and ocular toxicity.

C. Junot, H. Coste, Frédéric Donche, 2008, Bioorganic & Medicinal Chemistry.

Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.

M. Lambert, H. Xu, D. Grillot, 2007, Journal of medicinal chemistry.

Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).

C. Murray, Zehong Wan, V. Berdini, 2016, Journal of medicinal chemistry.

Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.

C. Murray, F. Holding, V. Berdini, 2016, Journal of medicinal chemistry.